Mesoblast (MEOBF) Research & Development (2014 - 2023)

Mesoblast has disclosed Research & Development across 10 years of filings, most recently posting -$32.3 million for Q2 2023.

• In Q2 2023, Research & Development fell 286.9% year-over-year to -$32.3 million; the TTM figure through Jun 2023 stood at -$52.8 million (down 403.8% YoY), while the FY2026 annual figure was -$30.5 million, down 278.2% from the prior year.
• Research & Development came in at -$32.3 million for Q2 2023 at Mesoblast, down from -$7.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $27.4 million in Q2 2021 to a low of -$40.9 million in Q1 2020.
• Average Research & Development over 5 years is -$11.0 million, with a median of -$11.4 million recorded in 2019.
• Year-over-year, Research & Development jumped 69.6% in 2021 and plunged 286.9% in 2023.
• Over 5 years, Research & Development stood at -$26.5 million in 2019, then jumped by 46.36% to -$14.2 million in 2020, then rose by 28.37% to -$10.2 million in 2021, then gained by 24.66% to -$7.7 million in 2022, then plunged by 320.67% to -$32.3 million in 2023.
• Per Business Quant data, the three most recent Research & Development figures were -$32.3 million in Q2 2023, -$7.1 million in Q1 2023, and -$7.7 million in Q4 2022.